



# ImmunAID project:

for a better diagnosis and management of  
autoinflammatory diseases



# Project governance

## Project Management Team



**Vassili Soumelis**  
Global Coordinator

**Bruno Fautrel**  
Clinical coordinator



**Arturo Hernández-Cervantes**  
Project manager

**Thibaut Dewael**  
WP1 Project manager  
(CHU Liège)



**Fanny Fernandes**  
Clinical project manager

**Frederic Peyrane**  
Financial  
/Innovation  
manager



## Steering Committee



**Thibaut Dewael**  
WP1 Project manager  
(CHU Liège)



**Dirk Föll**  
WP5 leader  
(WWU)



**Dominique De Seny**  
WP2 leader  
(Univ Liège)



**Vassili Soumelis**  
WP6 and WP8 leader  
(Inserm)



**Michael McDermott**  
WP3 leader  
(UnivLeeds)



**Bruno Fautrel**  
WP7 leader  
(AP-HP)



**Evangelos Andreakos**  
WP4 leader  
(BRFAA)



**Hélène Esperou**  
WP9 leader  
(Inserm)

# General context and current challenges in Systemic AutoInflammatory Diseases (SAID)

- **A complex and largely unknown set of rare diseases with unspecific symptoms (fever, rash, etc.)**
- **Very heterogeneous disease presentation within 2 main categories:**
  - ✓ Monogenic familial disorders (mSAID)
  - ✓ Phenotype-based SAIDs without known mutation (guSAID):
    - Recurrent Pericarditis
    - Adult-onset Still's disease or systemic juvenile idiopathic arthritis
    - Neutrophilic dermatosis
    - Schnitzler
    - Vasculitis (Kawasaki, Behçet, Takayasu arteritis)
    - Inflammation of unknown origin
    - Chronic/recurrent osteitis
- **Unmet medical needs**
  - ✓ Diagnosis is difficult: based on clinical signs and exclusion of other diseases
  - ✓ Diagnosis is long: up to 5 inappropriate treatments can be prescribed before the right diagnosis is made
- **Open biological questions**
  - ✓ Autoinflammation signatures related to SAID?
  - ✓ What is the dysregulation of inflammasome functions?
  - ✓ What is the cytokine network disequilibrium?

# Project objectives

## ■ Clinical objectives:

- ✓ To deliver a new, comprehensive and pathogenesis-driven classification of SAID
- ✓ To open the way to a rapid and accurate diagnosis across all the spectrum of SAID
- ✓ To improve patient management through adapted guidelines with more relevant treatment options

## ■ Biological objectives:

- ✓ To identify and validate novel Omics- and pathway-based diagnostic biomarkers: genetic mutations (or combinations of genetic mutations), translational dysregulation, proteomics disequilibrium or microbiome alteration associated with SAID
- ✓ To describe the potential dysregulation of inflammasome functions by studying known or suspected regulators and monitoring their functions in response to external stimuli
- ✓ To assess the role of cytokine network disequilibrium in the expression of SAIDs
- ✓ To explore inflammation resolution processes by measuring the activity of inflammation resolution effectors/regulators




# Scientific strategy

## European-wide cohort




Samples from a cohort of 1616 adults and paediatrics patients

## Exhaustive biological analyses




## Data integration and high-throughput analyses



## Outputs

- 1) New diagnostic biomarkers
- 2) Disentangle the spectrum of SAID
- 3) New omics- and pathogenesis-based SAID classifications
- 4) Robust clinical decision algorithm

# Workplan overview



# The ImmunAID consortium

24

Institutions from  
12 European  
countries



37

clinical centers  
in 11 countries



€15.8 million

funded by the Horizon 2020 program



Start date: May 1st, 2018

End date: April 30th, 2023